- Made Scientific and Streamline Bio have successfully validated an AI-driven robotic platform in a live cell therapy production environment at Made Scientific’s Princeton, NJ facility.
- The platform is being prepared for GMP integration to automate multi-step cell and gene therapy processes, reducing cost, complexity, and human error.
Made Scientific, a clinical and commercial-enabling cell therapy CDMO, has successfully completed initial validation of Streamline Bio’s AI-driven precision robotics platform in a live manufacturing environment. The work took place at Made Scientific’s Princeton, NJ facility and represents a step toward GMP integration, early-adopter programs, and commercial-scale implementation.
The fully AI-driven platform addresses key challenges in cell and gene therapy (CGT) manufacturing, including complex multi-step processes, high costs, and variable product quality. Designed for flexibility, the system integrates with diverse equipment and protocols, minimising the need for process changes or custom configurations. By automating manual, labor-intensive steps it reduces operator burden, mitigates human error, lowers costs, and enables personnel to focus on higher-value activities. Full data traceability is maintained through the platform’s digital-first design.
Next steps for the collaboration include preparing the platform for GMP deployment using Miltenyi CliniMACS Prodigy®, G-Rex®, and Fresenius-Kabi LOVO® systems. Integration into Made Scientific’s GMP cleanrooms will demonstrate orchestration of complex workflows and pave the way for broader commercial-scale use. Future studies will explore additional applications, including automated analytical and quality control testing.
“Today’s CGT processes are incredibly nuanced and complex,” said Rodney Rietze, Ph.D., President & CEO of Streamline Bio. “Streamline Bio’s robotic platform allows cell and gene therapy developers and manufacturers to respond with automation that’s not only smart and scalable, but inherently adaptive – enabling it to seamlessly integrate into your existing infrastructure with minimal costs and no workflow restrictions.”
“Streamline Bio is redefining manufacturing by offering an innovative, flexible and scalable platform aimed at making transformative therapies more accessible to patients. We’re excited to partner together as the companies explore how their technology can ultimately impact cost, process and product reproducibility, and time-to-clinic for emerging therapies.”
Syed T. Husain, Chairman & CEO of Made Scientific
